

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018044 A2

(51) International Patent Classification⁷: **A61P 35/00**,
29/00, A61K 31/497

(21) International Application Number:
PCT/GB2003/003653

(22) International Filing Date: 20 August 2003 (20.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0219660.8 23 August 2002 (23.08.2002) GB

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TONGE, David, William** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **TAYLOR, Sian, Tomiko** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BOYLE, Francis, Thomas** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **HUGHES, Andrew, Mark** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **JOHNSTONE, Donna** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park,

Macclesfield, Cheshire SK10 4TG (GB). **ASHFORD, Marianne, Bernice** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BARRASS, Nigel, Charles** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC USE

(57) Abstract: The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.



WO 2004/018044 A2

THERAPEUTIC USE

The present application refers to *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, hereafter "Compound (I)", and its use in the treatment of cancer in a warm blooded animal such as man. The invention also relates to the use of pharmaceutical compositions containing Compound (I), or a pharmaceutically acceptable salt thereof, in a method of treating cancer in a warm blooded animal such as man, and to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for use in a method of treating cancer in a warm blooded animal such as man. The invention also relates to the use of pharmaceutical compositions containing Compound (I), or a pharmaceutically acceptable salt thereof, in a method of treating pain in a warm blooded animal such as man, and to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for use treating pain in a warm blooded animal such as man.

Cancer affects an estimated 10 million people worldwide. This figure includes incidence, prevalence and mortality. More than 4.4 million cancer cases are reported from Asia, including 2.5 million cases from Eastern Asia, which has the highest rate of incidence in the world. By comparison, Europe has 2.8 million cases, North America 1.4 million cases, and Africa 627,000 cases.

In the UK and US, for example, more than one in three people will develop cancer at some point in their life. Cancer mortality in the U.S. is estimated to account for about 600,000 a year, about one in every four deaths, second only to heart disease in percent of all deaths, and second to accidents as a cause of death of children 1-14 years of age. The estimated cancer incidence in the U.S. is now about 1,380,000 new cases annually, exclusive of about 900,000 cases of non-melanotic (basal and squamous cell) skin cancer.

Cancer is also a major cause of morbidity in the UK with nearly 260,000 new cases (excluding non-melanoma skin cancer) registered in 1997. Cancer is a disease that affects mainly older people, with 65% of cases occurring in those over 65. Since the average life expectancy in the UK has almost doubled since the mid nineteenth century, the population at risk of cancer has grown. Death rates from other causes of death, such as heart disease, have fallen in recent years while deaths from cancer have remained relatively stable. The result is that 1 in 3 people will be diagnosed with cancer during their lifetime and 1 in 4 people will die from cancer. In people under the age of 75, deaths from cancer outnumber deaths from

diseases of the circulatory system, including ischaemic heart disease and stroke. In 2000, there were 151,200 deaths from cancer. Over one fifth (22 per cent) of these were from lung cancer, and a quarter (26 per cent) from cancers of the large bowel, breast and prostate.

Worldwide, the incidence and mortality rates of certain types of cancer (of stomach, breast, prostate, skin, and so on) have wide geographical differences which are attributed to racial, cultural, and especially environmental influences. There are over 200 different types of cancer but the four major types, lung, breast, prostate and colorectal, account for over half of all cases diagnosed in the UK and US. Prostate cancer is the fourth most common malignancy among men worldwide, with an estimated 400,000 new cases diagnosed annually, accounting for 3.9 percent of all new cancer cases.

Current options for treating cancers include surgical resection, external beam radiation therapy and / or systemic chemotherapy. These are partially successful in some forms of cancer, but are not successful in others. There is a clear need for new therapeutic treatments.

Non-steroidal anti-inflammatory drugs (NSAIDS) and opiates are the main classes of drugs in pain relief. However both possess undesirable side effects. NSAIDS are known to cause gastrointestinal irritation and opiates are known to be addictive. There is thus also a clear need for new treatments for the management and treatment of pain.

Recently, endothelin A receptor antagonists have been identified as potentially of value in the treatment of cancer (Cancer Research, 56, 663-668, February 15th, 1996 and Nature Medicine, Volume 1, Number 9, September 1999, 944-949).

The endothelins are a family of endogenous 21 amino acid peptides comprising three isoforms, endothelin-1 (ET-1), endothelin-2 and endothelin-3. The endothelins are formed by cleavage of the Trp²¹-Val²² bond of their corresponding proendothelins by an endothelin converting enzyme. The endothelins are among the most potent vasoconstrictors known and have a characteristic long duration of action. They exhibit a wide range of other activities including cell proliferation and mitogenesis, extravasation and chemotaxis, and also interact with a number of other vasoactive agents.

The endothelins are released from a range of tissue and cell sources including vascular endothelium, vascular smooth muscle, kidney, liver, uterus, airways, intestine and leukocytes. Release can be stimulated by hypoxia, shear stress, physical injury and a wide range of hormones and cytokines. Elevated endothelin levels have been found in a number of disease states in man including cancers.

The present invention concerns the surprising finding that Compound (**I**) is a particularly potent anti-cancer agent. Compound (**I**) is described as an endothelin receptor antagonist in WO96/40681, and although in WO96/40681 it is acknowledged that elevated endothelin levels have been found in a number of disease states in man including certain
5 cancers, there is no hint or suggestion that this compound would possess the particular beneficial efficacious, metabolic and toxicological profiles that makes it such a potent anti-cancer agent. WO96/40681 claims the endothelin receptors described therein solely for cardiovascular diseases. For example in the introduction it is stated these compounds are useful in the treatment of diseases or medical conditions including “hypertension, pulmonary
10 hypertension, cardiac or cerebral circulatory disease and renal disease”. The claims list the following medical disease states “hypertension, pulmonary hypertension, congestive heart failure, dyslipidaemia, atherosclerosis, restenosis, acute and chronic renal failure, ischaemic stroke, subarachnoid haemorrhage, intermittent claudication, critical limb ischaemia, asthma or organ failure after general surgery or transplantation”. There is no hint or suggestion from
15 WO96/40681 that this compound would possess the particular beneficial efficacious, metabolic and toxicological profiles that makes it such a potent anti-cancer agent. In fact, the present inventors have surprisingly established that Compound (**I**) is a specific endothelin-A (ET_A) antagonist and has no measurable activity against endothelin-B (ET_B).

The ET_A receptor has been shown, via a variety of mechanisms, to be the more
20 important pathological receptor of the two identified endothelin receptors in oncology: in the reduction of abnormal cell proliferation (Bagnato et. al., (1995), Clin Cancer Res 1, 1059-1066); as a anti-apoptotic (Wu Wang et. al., (1997), Biochem J., 328, 733-737); as an anti-angiogenic agent (Spinella et al., (2002), J. Biol. Chem, 277(31), 27850-27855); and as an inhibitor of bone metastases (Guise et. al., ASCO (2000) abstract 331 and Nelson, et. al.,
25 (1999), Urology 53, 1063-1069) in addition to mediating pain which is a common co-morbidity in cancer. It has been shown (Dahlof et al., (1990), J Hypertens, 8, 811- 817) that large doses of endothelin-1 causes pain, and causes pain sensitization, but that this can be inhibited by an ET_A antagonist (e.g. Davar et al., (1998), Neuroreport 9, 2279-2283 and De Mello et al., (1998), Pain, 77, 261-269). Therefore in another aspect of the invention,
30 Compound (**I**) is administered for the prevention or treatment of pain mediated by the endothelin system, in particular that associated with elevated endothelin-1 levels.

Conversely, there is emerging evidence (e.g. Cattaruzza et. al., (2002), FASEB J. 14(7), 991-998 and Okazawa et. al., (1998), J Biol Chem, 273, 12581-12592) that the ET_B

receptor is involved in apoptotic signalling. The blocking of pro-apoptotic pathways would be undesirable in the treatment of cancer, hence a compound that specifically targeted the ET_A receptor while leaving the ET_B receptor unaffected would be of the greatest utility in the treatment of cancer. Compound (I) is such a compound.

5 Compound (I) by acting specifically on the ET_A receptor has many advantages over endothelin antagonists that also have measurable ET_B activity. For instance Compound (I) could be administered to a patient without the administrator or prescribing medical practitioner needing to titrate the dose of Compound (I) looking for signs of ET_B activity (for example oedema). Furthermore, larger doses could potentially be administered because there
10 would be no ET_B side effects.

Another disadvantage of ET_B inhibition is that it causes a rise in plasma endothelin. Potentially, over the course of treatment, for a mixed ET_A / ET_B inhibitor, or a compound that selectively targeted the ET_A receptor, but still had measurable ET_B activity, this would result in increasingly larger doses of inhibitor being needed to have the same beneficial ET_A effects.
15 A specific ET_A inhibitor would not encounter this problem.

Therefore according to the present invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm blooded animal such as man.

In one aspect, where Compound (I), or a pharmaceutically acceptable salt thereof, is
20 referred to this refers to the compound only. In another aspect this refers to a pharmaceutically acceptable salt of Compound (I).

According to another feature of the present invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer in a warm blooded animal such as man.

25 According to a further feature of this aspect of the invention there is provided a method of treating cancer which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically
30 acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the treatment of cancer in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the reduction of abnormal proliferation in a

cancerous cell or inducing differentiation of a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the
5 reduction of abnormal proliferation in a cancerous cell or inducing differentiation of a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided a method for reducing abnormal proliferation in a cancerous cell or inducing differentiation of a cancerous cell which comprises administering an effective amount of Compound (I), or a pharmaceutically
10 acceptable salt thereof, to a warm blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the reduction of abnormal proliferation in a cancerous cell or inducing differentiation of
15 a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in inducing apoptosis in a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a
20 pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inducing apoptosis in a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided a method of inducing apoptosis in a cancerous cell which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

25 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in inducing apoptosis in a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a
30 pharmaceutically acceptable salt thereof, as an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an

anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell in a warm blooded animal such as man.

In another aspect of the invention there is provided a method of providing an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell which
5 comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for
10 use as an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell in a warm blooded animal such as man.

By the term "vascular targeting agent" it is to be understood that the site of action of Compound (I) would be on the vasculature itself rather than the tumour.

In another aspect of the invention there is provided the use of Compound (I), or a
15 pharmaceutically acceptable salt thereof, as an anti-angiogenic agent in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an anti-angiogenic agent in a warm blooded animal such as man.

20 In another aspect of the invention there is provided a method of providing an anti-angiogenic effect which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically
25 acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use as an anti-angiogenic agent in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man.

30 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man.

In another aspect of the invention there is provided a method of inhibiting bone metastases and inhibiting invasion which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

5 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man.

10 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of bone metastases in a warm blooded animal such as man.

 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an
15 inhibitor of bone metastases in a warm blooded animal such as man.

 In another aspect of the invention there is provided a method of inhibiting bone metastases which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

 According to a further feature of this aspect of the invention there is provided a
20 pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use as an inhibitor of bone metastases in a warm blooded animal such as man.

 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the prevention of bone metastases in a warm
25 blooded animal such as man.

 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention of bone metastases in a warm blooded animal such as man.

 In another aspect of the invention there is provided a method of preventing bone
30 metastases which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically

acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention of bone metastases in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of bone metastases in a warm
5 blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of bone metastases in a warm blooded animal such as man.

In another aspect of the invention there is provided a method of treating bone
10 metastases which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for
15 use in the treatment of bone metastases in a warm blooded animal such as man.

In a further aspect of the invention, there is provided the inhibition, treatment and / or prevention of bone metastases, as described herein, wherein the bone metastases are as a result of renal, thyroid, lung, breast or prostate cancer.

In another aspect of the invention there is provided the use of Compound (I), or a
20 pharmaceutically acceptable salt thereof, in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm
25 blooded animal such as man.

In another aspect of the invention there is provided a method of treating pain associated with elevated endothelin-1 production which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

30 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for

use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the prevention or treatment of pain in a warm
5 blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of pain in a warm blooded animal such as man.

In another aspect of the invention there is provided a method of treating pain which
10 comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the prevention or treatment of pain associated with stimulation of the ET_A receptor in a warm blooded animal such as man.

15 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of pain associated with stimulation of the ET_A receptor in a warm blooded animal such as man.

In another aspect of the invention there is provided a method of treating pain
20 associated with stimulation of the ET_A receptor which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.

Where cancer is referred to, particularly it refers to oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposi sarcoma,
25 ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) - gastric cancer, head and neck cancer, renal cancer, lymphoma and leukaemia. More particularly it refers to prostate cancer. In addition, more particularly it refers to SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer. In addition, more
30 particularly it refers to SCLC. In addition, more particularly it refers to NSCLC. In addition, more particularly it refers to colorectal cancer. In addition, more particularly it refers to ovarian cancer. In addition, more particularly it refers to breast cancer. Furthermore, more particularly it refers to bladder cancer, oesophageal cancer, gastric cancer, melanoma, cervical

cancer and / or renal cancer. In addition it refers to endometrial, liver, stomach, thyroid, rectal and / or brain cancer. In another aspect of the invention, the cancer is not melanoma. In another embodiment of the invention, particularly the cancer is in a metastatic state, and more particularly the cancer produces metastases to the bone. In a further embodiment of the invention, particularly the cancer is in a metastatic state, and more particularly the cancer produces skin metastases. In a further embodiment of the invention, particularly the cancer is in a metastatic state, and more particularly the cancer produces lymphatic metastases. In a further embodiment of the invention, the cancer is in a non-metastatic state.

It is to be understood that when the cancer is in a metastatic state, that Compound (I) acts at both the primary tumour site and the metastases. Compound (I) both prevents, treats and inhibits metastases.

In one aspect of the invention, where pain is referred to, this is pain associated with raised endothelin-1 levels. In another aspect of the invention this is pain associated with stimulation of the ET_A receptor resulting from situations where ET_B down-regulation has occurred leading to abnormal ET_A stimulation and/or elevation of endothelin-1 levels. Particularly this is pain associated with cancer. More particularly it is pain associated with prostate cancer.

According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention or treatment of pain associated with stimulation of the ET_A receptor in a warm blooded animal such as man.

Additionally, Compound (I) is expected to be useful in the treatment and/or prophylaxis of pain of different origins and causes, including acute as well as chronic pain states. Examples are pain caused by chemical, mechanical, radiation (including sunburn), thermal (including burns), infectious or inflammatory tissue trauma or cancer, postoperative pain, post-partum pain, the pain associated with joint conditions (such as rheumatoid arthritis and osteoarthritis), pain associated with dental conditions (such as dental caries and gingivitis), myofascial and low back pain, pain associated with bone disorders (such as osteoporosis, hypercalcaemia of malignancy and Paget's disease) and the pain associated with sports injuries and sprains.

Also neuropathic pain conditions of central or peripheral origin could be treated or prevented with Compound (I). Examples of these pain conditions are pain associated with

trigeminal neuralgia, pain associated with postherpetic neuralgia (PHN), pain associated with diabetic mono/poly neuropathy, pain associated with nerve trauma, pain associated with spinal cord injury, pain associated with central post stroke, pain associated with multiple sclerosis and pain associated with Parkinson's disease.

- 5 Other pain states of visceral origin such as caused by ulcer, dysmenorrhea, endometriosis, irritable bowel syndrome, dyspepsia, pelvic pain etc. could also be treated or prevented with Compound (I).

Additionally, Compound (I) is expected to be useful in the treatment and/or prophylaxis of additional types of pain for example complex regional pain syndrome,
10 vasospastic/ischemic pains (e.g. Raynaud syndrome) and bone pain.

A further aspect of the invention is to use Compound (I) for oral treatment of neuropathic or central pain states.

Suitable pharmaceutically-acceptable salts include, for example, salts with alkali metal (such as sodium, potassium or lithium), alkaline earth metals (such as calcium or magnesium),
15 ammonium salts, and salts with organic bases affording physiologically acceptable cations, such as salts with methylamine, dimethylamine, trimethylamine, piperidine and morpholine. In addition, suitable pharmaceutically-acceptable salts include, pharmaceutically-acceptable acid-addition salts with hydrogen halides, sulphuric acid, phosphoric acid and with organic acids such as citric acid, maleic acid, methanesulphonic acid and p-toluenesulphonic acid.

20 **Legends to Figures**

Figure 1: This is a Western Blot showing inhibition of ET-1 induced MAPK phosphorylation with Compound (I) in the osteoblast cell line MC3T3.E1/J1 from study 2 below. The proteins have been run on a gel then transferred over to a nitrocellulose membrane, where they are probed for using the primary and secondary antibodies. The

- 25 following abbreviations are used:

SCM: serum containing media

SFM: serum free media

Figure 2: This is a graph depicting, inhibition of ET-1 induced MAPK phosphorylation with Compound (I) in the osteoblast cell line MC3T3.E1/J1 also from study 2.

- 30 The following *in vivo* and *in vitro* studies can be used to determine the efficacy of Compound (I) in oncology.

1) Endothelin human receptor binding assay

Human recombinant ET_A or ET_B receptors were expressed in mouse erythroleukaemic (MEL) cells and membranes prepared for competition binding studies using ¹²⁵I-labelled ET-1 as the radioligand. Incubations were carried out in triplicate in the presence of Compound (I),
5 10⁻¹⁰ - 10⁻⁴ M in half log increments, and inhibition of ET-1 binding was expressed as a geometric mean pIC₅₀ value with 95% confidence limits.

Results

The pIC₅₀ (negative log of the concentration of compound required to displace 50% of the ligand) for Compound (I) at the ET_A receptor was 8.27 [8.23 - 8.32] (n=4). Displacement
10 curves were normal with slopes close to unity. Compound (I) had no measurable affinity for the ET_B receptor with a mean displacement of 1.2 ± 0.7% (n=3) at a concentration of 10⁻⁴M, a figure well within the limits of sensitivity of the assay.

Conclusion

Compound (I) is a high affinity ligand for the human ET_A receptor and is ET_A
15 specific, having no significant ET_B receptor affinity.

2) Compound (I) as a treatment for Metastatic Cancer: Osteoblast data - Inhibition of ET-1 induced MAPK stimulation with Compound (I)

Compound (I) may well have a role in the treatment of not only primary tumours but also metastatic tumours and the pathological production of new bone in and around metastatic
20 deposits. Described below is an experiment demonstrating the utility of Compound (I) in treating the osteoblastic bone pathology.

The important clinical pathology seen in the bone metastatic regions of patients with advanced prostate cancer presents as an inappropriate osteoblastic stimulation, i.e. the presence of prostatic tumour metastases in bone results in the net production of new bone and
25 eventually an increase in bone density around the metastatic deposit (reviewed in Cancer Metastasis Rev. 2001; 20(3-4):333-49). The hypothesised mechanism behind this pathology is a release of ET-1 from the metastatic prostate cell in the early establishment of the secondary bone tumour.

ET-1 stimulation of the osteoblast has been described as the key step in the
30 pathological formation of new bone in prostate bone metastasis (Invest New Drugs. 2002; 20(2):173-82). It has been shown that ET-1 acts to directly induce proliferation and differentiation of the osteoblast, as well as stimulate the osteoblast to produce other growth factors, by stimulation of the ET_A receptor and subsequent phosphorylation of MAP kinase

(Bone. 1999; 24(4):315-20 and J Bone Miner Res. 2002; 17(10):1774-84). In this way stimulation of the ET_A receptor causes both growth of bone and also, by release of growth factors into the local environment, survival and growth of the metastatic tumour cell. The tumour cells and osteoblastic cells in a metastatic deposit therefore participate in a “vicious cycle” in which their proliferative responses support each other, overcoming the normal regulatory mechanisms which control and limit bone formation (Nat Rev Cancer. 2002; 2(8): 584-93).

In the experiments described below the present inventors first demonstrate the ability of ET-1 to stimulate MAP kinase in osteoblastic cells. This stimulation promotes proliferation of the cells and activation of the pathways shown to be important in the release of growth factors from the osteoblast.

The inventors then demonstrate that Compound (**I**), an ET_A antagonist is an effective antagonist of this ET-1 stimulation.

Method

The MC3T3. E1/J1 cell line was isolated from a parental cell line, MC3T3-E1 (available from Invitrogen), which had in turn been derived from newborn C57BL/6 mouse calvaria. The MC3T3 E1/J1 line is described as an osteoblastic line. To initiate the experiments described below, MC3T3.E1/J1 cells were plated at a density of 2.4×10^4 cells/well (24 well plates) in serum containing media and incubated for 48 hours. The cells were washed twice in PBS and re-incubated for approximately 17 hours in serum starvation media.

At this stage, cells were then incubated with or without Compound (**I**) for 30 minutes then stimulated with growth factor (PDGF or ET-1) for 3 minutes. All media was then removed and the cells lysed and stored at -20°C for electrophoresis/western blot, which localized phosphorylated MAPK and phosphorylated Akt probing with anti-phospho-p44/42 MAPK (Thr 202/204) and anti-Phospho AKT (Ser 473) antibodies (both commercially available from Cell Signalling Technology). The protein bands were quantitated by densitometry, and plotted as arbitrary densitometry units. Phosphorylated MAPK levels were normalised to total MAPK levels.

Results

Stimulation of cells with ET-1 for 3 minutes resulted in increased phosphorylation of MAPK in the osteoblast cell line MC3T3.E1/J1. Stimulation of the cells with a standard

growth factor, PDGF, also resulted in increased phosphorylation of MAPK. Compound (I) inhibited ET-1-induced MAPK phosphorylation in osteoblasts.

Table 1 Inhibition of ET-1 induced MAPK phosphorylation with Compound (I) in the osteoblast cell line MC3T3.E1/J1

| Environment | Average |
|----------------------------|---------|
| Complete Media | 151.70 |
| Serum Free Media | 100.00 |
| ET-1 100nm | 312.78 |
| ET-1 100nm | 369.85 |
| + Compound (I) 20 μ m | 109.18 |
| + Compound (I) 10 μ m | 105.15 |
| + Compound (I) 1 μ m | 157.41 |
| + Compound (I) 0.1 μ m | 422.11 |

Table 1

This data is represented in Figures 1 and 2.

Note: The above experiment is not reliant on use of the particular MC3T3.E1/J1 cell line, it could, for example, be performed using the commercially available parental cell line MC3T3-E1.

3) Compound (I) as an inhibitor of angiogenesis

ET_A receptor activation by ET-1 contributes to tumour growth and progression, mediated by various mechanisms in the literature to suggest that specifically inhibiting ET_A will produce beneficial effects on primary tumours quite separate to its effects on bone metastases. These mechanisms include anti-apoptosis, direct and indirect growth promotion and promotion of cell motility (Nat Rev Cancer. 2003; 3(2): 110-6).

Of more recent and increasing interest is the role of ET-1 mediated by the ET_A receptor as key players in tumour angiogenesis (J Cardiovasc Pharmacol. 2000; 36: S135-9). Mechanistic studies have now shown that the ET_A receptor is important in the production of the potent angiogenic factor VEGF (Life Sci. 1998; 63(6): 477-84) by direct induction of a hypoxia-inducible factor, HIF-1 α (J Biol Chem. 2002; 277: 27850-5). The increasing literature to support the role of endothelin and the ET_A receptor in tumour angiogenesis was reviewed very recently by Bagnato and Spinella, (Trends Endocrinol Metab. 2003; 14(1): 44-50).

In the experiment described below we show the effect of Compound (I) on the angiogenesis induced by newly formed tumours following human tumour cell inoculation in animal models.

Method

5 Tumour cells were inoculated intra-dermally in nude mice, Compound (I) 25 or 50 mg/kg or vehicle was given once daily p.o. with the first dose given on the day after cell implantation and the mice were sacrificed 5 days later. A 1 cm² area with the tumour at the centre was examined and the number of blood vessels bifurcations within that area supplying the tumour were counted. The number of vessels supplying tumours from animals treated with
10 test drug and vehicle were compared and the effect of Compound (I) was calculated as a percentage reduction of vessel count.

Results

Compound (I) caused reductions in blood vessel density around tumours in treated animals compared to vehicle controls. Reductions in vessel counts by Compound (I) were
15 seen around tumours induced by both colon and prostate cell lines in five *in vivo* studies.

Table 2 Inhibition of angiogenesis in primary tumours caused by Compound (I)

| Cell Line | Tumour Type | Compound (I) dose (mg/kg) | Inhibition of vessel count ¹ |
|-----------|-------------|---------------------------|---|
| LOVO | Colon | 50 | 20% (P=0.001) |
| LOVO | Colon | 50 | 28% (P<0.001) |
| LOVO | Colon | 25 | 28% (P<0.001) |
| DU145 | Prostate | 50 | 30% (P<0.05) |
| DU145 | Prostate | 25 | 38% (P<0.001) |

Table 2

¹ statistically analyzed by the ANOVA test compared to vehicle controls

The above cells lines are commercially available. One source is the ATCC (American
20 Type Culture Collection). LOVO has ATCC No = CCL-229. DU145 has ATCC No = HTB-81.

Discussion

We have shown that, *in vitro*, Compound (I) is an effective inhibitor of ET-1 mediated activation of MAP kinase in osteoblasts as well as being effective in inhibiting angiogenesis
25 in primary tumours *in vivo*. This confirms the potential for this agent as a therapy in metastatic prostate cancer as it may have beneficial effects in preventing pathological bone density increases (by inhibition of osteoblastic proliferation), mediated by MAPK pathway as

well as inhibiting the release of growth factors which support the survival and growth of tumour cells in the bone microenvironment in addition to anti-angiogenesis effect at the primary tumour.

4) Compound (I) as an endothelin receptor antagonist in the human endothelin system

5 Human forearm blood flow can be assessed by temporarily impeding the venous drainage from the arm by the application of a pneumatic cuff on the upper arm, which is then inflated to just above venous pressure. The resulting arterial flow into the arm with no corresponding venous drainage leads to engorgement and swelling of the forearm, which can be detected with sensitive strain gauges. Infusion of the arterial vasoconstrictor ET-1 into the
10 brachial artery leads to a reduction in forearm distension due to decreased arterial inflow. This vasoconstriction is mediated via endothelin receptors on the vascular endothelium and associated smooth muscle.

Method

A study was performed to investigate the ability of Compound (I) to antagonise the
15 vasoconstrictor effect of ET-1 via endothelin receptors in this model in healthy male subjects aged 18-65. Eight subjects received single oral doses of 10 mg Compound (I), 30mg Compound (I) and placebo in a randomised, double blind manner on study days at least 7 days apart. Forearm vasoconstriction in response to ET1 was assessed between 2 and 4 hours post dosing with Compound (I).

20 Results

Overall, Compound (I) produced a statistically significant reduction in forearm blood flow in response to infused ET-1 compared to placebo ($p=0.0210$) with evidence of a dose response between the doses investigated. This demonstrates that Compound (I) is an endothelin receptor antagonist in the human endothelin system.

25 5) Compound (I) in a Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of Compound (I) given Orally Once Daily in Patient With Metastatic Prostate Cancer

The following study can be undertaken to determine the maximum well tolerated dose (MWTDD) of Compound (I) in subjects with metastatic prostate cancer. This study will allow
30 you to observe the effect of Compound (I) on prostate-specific antigen (PSA), observe the effect of Compound (I) on a serological biomarker of bone metastasis and provide you with pharmacokinetic characterization of Compound (I) in subjects with metastatic prostate cancer.

Method

Patients with prostate cancer who have documented bone metastases (confirmed by bone scan within 3 months of study entry) can be used for this study. Compound (I) can be given orally once daily in tablet form. 120 mg can be used as the starting dose. Subjects can
5 be given study medication for 28 days or until withdrawal criteria are met. Each dose level can recruit up to three subjects with metastatic prostate cancer.

A formal assessment of tolerability can be made in each subject following one week of Compound (I) administration. Dose escalation can occur when two subjects in any cohort have not experienced a dose limiting toxicity (DLT) following one week of continuous
10 Compound (I) administration. The dose can escalate by a factor of two at each step. If one subject at a particular dose level has a DLT, then two additional subjects at the same dose level must not experience DLTs in order to escalate to the next dose level.

Subjects can continue therapy for twenty eight days unless the withdrawal criteria are met. When a minimum of two subjects in any cohort have been given a dose that is
15 considered to be not well tolerated at any time point after administration, dose escalation will end, and the closest dose below this will be taken as the MWTD.

The following outcomes can be observed:

- Incidence and severity of adverse events;
- PSA concentration (total and ratio of free to total) at 1, 2, and 4 weeks in subjects
20 treated with Compound (I);
- Change in PSA (total and ratio of free to total) from before Compound (I) administration to 1, 2 and 4 weeks after Compound (I) administration;
- Change in a serum marker of bony metastatic involvement (bone alkaline phosphatase) from the level before Compound (I) administration to levels after 1, 2,
25 and 4 weeks of Compound (I) administration; and
- Plasma concentrations and variables of Compound (I) following a single dose and multiple doses at steady state.

Testing for pain relief

The analgesic effect of Compound (I) may be measured, for example, in the murine
30 model of cancer pain described by Wacnik et al., Journal of Neuroscience (2001), 21, 9355.

In a further embodiment of the present invention Compound (I), or a pharmaceutically acceptable salt thereof, is administered to a cell or individual prior to the development of cancer. For example, a person at risk of developing cancer may be treated with Compound (I),

or a pharmaceutically acceptable salt thereof, to prevent or inhibit the development of cancer and/or to prevent the development of metastases.

Compound (I), or a pharmaceutically acceptable salt thereof, can be administered for therapeutic or prophylactic use to a warm blooded animal such as man by methods known in the art. Administration can occur directly at the tumour site, or particularly, systemic administration.

Compound (I), or a pharmaceutically acceptable salt thereof, can be administered for therapeutic or prophylactic use to a warm blooded animal such as man in the form of conventional pharmaceutical compositions. The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients. For example, Compound (I) can be formulated as a tablet using the following excipients:

Compound (I);

Lactose monohydrate (filler);

Croscarmellose sodium (disintegrant);

Povidone (binder);

Magnesium stearate (lubricant);

Hypromellose (film coat component);

Polyethylene glycol 300 (film coat component); and

Titanium dioxide (film coat component).

The amount of Compound (I), or a pharmaceutically acceptable salt thereof, administered would be that sufficient to provide the desired pharmaceutical effect. For instance, Compound (I) could be administered to a warm-blooded animal orally, at a unit dose less than 1g daily. Particularly Compound (I) could be administered to a warm-blooded animal, at a unit dose of less than 250 mg per day. In another aspect of the invention, Compound (I) could be administered to a warm-blooded animal, at a unit dose of less than 130 mg per day. In a further aspect of the invention, Compound (I) could be administered to a warm-blooded animal, at a unit dose of less than 50 mg per day.

Claims

1. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the
5 manufacture of a medicament for use in the treatment of cancer in a warm blooded animal such as man.
2. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the reduction of abnormal proliferation
10 in a cancerous cell or inducing differentiation of a cancerous cell in a warm blooded animal such as man.
3. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inducing apoptosis in a cancerous cell
15 in a warm blooded animal such as man.
4. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an anti-angiogenic and vascular targeting agent in blood vessels a cancerous cell in a warm blooded animal such as man.
20
5. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an anti-angiogenic agent in a warm blooded animal such as man.
- 25 6. The use according to claim 1 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia.
30
7. The use according to claim 1 wherein the cancer is prostate cancer.

8. The use according to claim 1 wherein the cancer is SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer.
9. The use according to claim 1 wherein the cancer is bladder cancer, oesophageal
5 cancer, gastric cancer, melanoma, cervical cancer and / or renal cancer.
10. The use according to claim 1 wherein the cancer is endometrial, liver, stomach, thyroid, rectal and / or brain cancer.
- 10 11. The use according to claim 1 wherein the cancer is SCLC.
12. The use according to claim 1 wherein the cancer is NSCLC.
13. The use according to claim 1 wherein the cancer is colorectal cancer.
15
14. The use according to claim 1 wherein the cancer is ovarian cancer.
15. The use according to claim 1 wherein the cancer is breast cancer.
- 20 16. The use according to any one of claims 1 and 6-15 wherein the cancer is in a metastatic state.
17. The use according to any one of claims 1 and 6-15 wherein the cancer is in a non-metastatic state.
25
18. The use according to any one of claims 1 and 6-15 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.
19. The use of the compound according to claim 1, or a pharmaceutically acceptable salt
30 thereof, in the manufacture of a medicament for use as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man.

20. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an inhibitor of bone metastases in a warm blooded animal such as man.

5 21. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention of bone metastases in a warm blooded animal such as man.

22. The use of the compound according to claim 1, or a pharmaceutically acceptable salt
10 thereof, in the manufacture of a medicament for use in the treatment of bone metastases in a warm blooded animal such as man.

23. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide), or a pharmaceutically acceptable salt thereof, in the
15 manufacture of a medicament for use in the prevention or treatment of pain in a warm blooded animal such as man.

24. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the
20 manufacture of a medicament for use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm blooded animal such as man.

25. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the
25 manufacture of a medicament for use in the prevention or treatment of pain associated with stimulation of the ET_A receptor in a warm blooded animal such as man.




Figure 1




Figure 2

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018044 A3

(51) International Patent Classification⁷: **A61P 35/00**,
29/00, A61K 31/497

(GB). **BARRASS, Nigel, Charles** [GB/GB]; AstraZeneca
R & D Alderley, Alderley Park, Macclesfield, Cheshire
SK10 4TG (GB).

(21) International Application Number:
PCT/GB2003/003653

(74) **Agent: ASTRAZENECA**; Global Intellectual Property,
Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(22) International Filing Date: 20 August 2003 (20.08.2003)

(25) Filing Language: English

(81) **Designated States (national)**: AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) **Priority Data**:
0219660.8 23 August 2002 (23.08.2002) GB

(84) **Designated States (regional)**: ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) **Applicant (for all designated States except MG, US): AS-
TRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(71) **Applicant (for MG only): ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only): TONGE, David,**
William [GB/GB]; AstraZeneca R & D Alderley, Alderley
Park, Macclesfield, Cheshire SK10 4TG (GB). **TAYLOR,**
Sian, Tomiko [GB/GB]; AstraZeneca R & D Alderley,
Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
BOYLE, Francis, Thomas [GB/GB]; AstraZeneca R
& D Alderley, Alderley Park, Macclesfield, Cheshire
SK10 4TG (GB). **HUGHES, Andrew, Mark** [GB/GB];
AstraZeneca R & D Alderley, Alderley Park, Maccles-
field, Cheshire SK10 4TG (GB). **JOHNSTONE, Donna**
[GB/GB]; AstraZeneca R & D Alderley, Alderley Park,
Macclesfield, Cheshire SK10 4TG (GB). **ASHFORD,**
Marianne, Bernice [GB/GB]; AstraZeneca R & D Alder-
ley, Alderley Park, Macclesfield, Cheshire SK10 4TG

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) **Date of publication of the international search report:**
6 May 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) **Title:** N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-'1,3,4-OXADIAZOL-2-YL!PHENYL)PYRIDINE-3
SULPHONAMIDE AS AN ANTICANCER AGENT

(57) **Abstract:** The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a
pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.



WO 2004/018044 A3

INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/GB 03/03653

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P35/00 A61P29/00 A61K31/497

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 96/40681 A (ZENECA LTD) 19 December 1996 (1996-12-19) cited in the application page 2, line 6 page 21, lines 28-30 claim 11 | 1-25 |
| Y | WO 01/44239 A (BRISTOL MYERS SQUIBB CO ;MURUGESAN NATESAN (US); GU ZHENGXIANG (US) 21 June 2001 (2001-06-21) page 48, paragraph 1 ----- -/- | 1-22 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

26 February 2004

Date of mailing of the international search report

12.03.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Skjöldebrand, C

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 03/03653

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Y | CARDUCCI M A ET AL: "ENDOTHELIN RECEPTOR ANTAGONIST, ABT-627, FOR PROSTATE CANCER: INITIAL TRIAL RESULTS" JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 161, no. 4, SUPPL, April 1999 (1999-04), page 176, XP001037609 ISSN: 0022-5347 abstract | 1-22 |
| Y | ----- NELSON J B ET AL: "THE ROLE OF ENDOTHELIN-1 AND ENDOTHELIN RECEPTOR ANTAGONISTS IN PROSTATE CANCER" BJU INTERNATIONAL, BLACKWELL SCIENCE, OXFORD, GB, vol. 85, no. SUPPL 2, April 2000 (2000-04), pages 45-48, XP008007943 ISSN: 1464-4096 the whole document | 1-22 |
| Y | ----- JARVIS M F ET AL: "ABT-627, AN ENDOTHELIN ETA RECEPTOR-SELECTIVE ANTAGONIST, ATTENUATES TACTILE ALLODYNIA IN A DIABETIC RAT MODEL OF NEUROPATHIC PAIN" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 388, no. 1, 24 January 2000 (2000-01-24), pages 29-35, XP001152675 ISSN: 0014-2999 abstract | 23-25 |
| Y | ----- WO 02/49630 A (SQUIBB BRISTOL MYERS CO ; LEBWOHL DAVID E (US)) 27 June 2002 (2002-06-27) claims | 23-25 |
| Y | ----- DATABASE WPI Section Ch, Week 200163 Derwent Publications Ltd., London, GB; Class B03, AN 2001-565331 XP002271565 & WO 01/60370 A (YAMANOUCHI PHARM CO LTD) 23 August 2001 (2001-08-23) abstract | 23-25 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 03/03653

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22

The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-
'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide in the
manufacture of a medicament for use in the treatment of
cancer in a warm-blooded animal.

2. claims: 23-25

The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-
'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide in the
manufacture of a medicament for use in the prevention and
treatment of pain in a warm-blooded animal.

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018044 A3

(51) International Patent Classification⁷: **A61P 35/00**,
29/00, A61K 31/497

R & D Alderley, Alderley Park, Macclesfield, Cheshire
SK10 4TG (GB).

(21) International Application Number:
PCT/GB2003/003653

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(22) International Filing Date: 20 August 2003 (20.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0219660.8 23 August 2002 (23.08.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except MG, US*): **AS-
TRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **TONGE, David**,
William [GB/GB]; AstraZeneca R & D Alderley, Alderley
Park, Macclesfield, Cheshire SK10 4TG (GB). **TAYLOR**,
Sian, Tomiko [GB/GB]; AstraZeneca R & D Alderley,
Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
BOYLE, Francis, Thomas [GB/GB]; AstraZeneca R
& D Alderley, Alderley Park, Macclesfield, Cheshire
SK10 4TG (GB). **HUGHES, Andrew, Mark** [GB/GB];
AstraZeneca R & D Alderley, Alderley Park, Maccles-
field, Cheshire SK10 4TG (GB). **JOHNSTONE, Donna**
[GB/GB]; AstraZeneca R & D Alderley, Alderley Park,
Macclesfield, Cheshire SK10 4TG (GB). **ASHFORD**,
Marianne, Bernice [GB/GB]; AstraZeneca R & D Alder-
ley, Alderley Park, Macclesfield, Cheshire SK10 4TG
(GB). **BARRASS, Nigel, Charles** [GB/GB]; AstraZeneca

Published:

— with international search report

(88) Date of publication of the international search report:
6 May 2004

Date of publication of the revised international search
report: 24 June 2004

(15) Information about Correction:
see PCT Gazette No. 26/2004 of 24 June 2004, Section II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-'1,3,4-OXADIAZOL-2-YL!PHENYL)PYRIDINE-3
SULPHONAMIDE AS AN ANTICANCER AGENT

(57) Abstract: The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a
pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.



WO 2004/018044 A3

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/GB 03/03653

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P35/00 A61P29/00 A61K31/497

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | WO 96/40681 A (ZENECA LTD) 19 December 1996 (1996-12-19) cited in the application page 2, line 6 page 21, lines 28-30 claim 11 | 1-25 |
| Y | WO 01/44239 A (BRISTOL MYERS SQUIBB CO ;MURUGESAN NATESAN (US); GU ZHENGXIANG (US) 21 June 2001 (2001-06-21) page 48, paragraph 1 ----- -/-- | 1-22 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

26 February 2004

Date of mailing of the international search report

12 03. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Skjöldebrand, C

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/GB 03/03653

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | CARDUCCI M A ET AL: "ENDOTHELIN RECEPTOR ANTAGONIST, ABT-627, FOR PROSTATE CANCER: INITIAL TRIAL RESULTS" JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 161, no. 4, SUPPL, April 1999 (1999-04), page 176, XP001037609 ISSN: 0022-5347 abstract | 1-22 |
| Y | NELSON J B ET AL: "THE ROLE OF ENDOTHELIN-1 AND ENDOTHELIN RECEPTOR ANTAGONISTS IN PROSTATE CANCER" BJU INTERNATIONAL, BLACKWELL SCIENCE, OXFORD, GB, vol. 85, no. SUPPL 2, April 2000 (2000-04), pages 45-48, XP008007943 ISSN: 1464-4096 the whole document | 1-22 |
| Y | JARVIS M F ET AL: "ABT-627, AN ENDOTHELIN ETA RECEPTOR-SELECTIVE ANTAGONIST, ATTENUATES TACTILE ALLODYNIA IN A DIABETIC RAT MODEL OF NEUROPATHIC PAIN" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 388, no. 1, 24 January 2000 (2000-01-24), pages 29-35, XP001152675 ISSN: 0014-2999 abstract | 23-25 |
| Y | WO 02/49630 A (SQUIBB BRISTOL MYERS CO ; LEBWOHL DAVID E (US)) 27 June 2002 (2002-06-27) claims | 23-25 |
| Y | DATABASE WPI Section Ch, Week 200163 Derwent Publications Ltd., London, GB; Class B03, AN 2001-565331 XP002271565 & WO 01/60370 A (YAMANOUCHI PHARM CO LTD) 23 August 2001 (2001-08-23) abstract | 23-25 |

INTERNATIONAL SEARCH REPORT

In international application No.
PCT/GB 03/03653

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22

The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-
'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide in the
manufacture of a medicament for use in the treatment of
cancer in a warm-blooded animal.

2. claims: 23-25

The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-
'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide in the
manufacture of a medicament for use in the prevention and
treatment of pain in a warm-blooded animal.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/03653

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9640681 | A | 19-12-1996 | AT 209200 T | 15-12-2001 |
| | | | AU 715041 B2 | 13-01-2000 |
| | | | AU 5840396 A | 30-12-1996 |
| | | | BR 9608611 A | 11-05-1999 |
| | | | CA 2219742 A1 | 19-12-1996 |
| | | | CN 1192739 A , B | 09-09-1998 |
| | | | CZ 9703887 A3 | 18-03-1998 |
| | | | DE 69617236 D1 | 03-01-2002 |
| | | | DE 69617236 T2 | 11-07-2002 |
| | | | DK 832082 T3 | 21-05-2002 |
| | | | EP 0832082 A1 | 01-04-1998 |
| | | | ES 2168487 T3 | 16-06-2002 |
| | | | WO 9640681 A1 | 19-12-1996 |
| | | | HK 1005801 A1 | 20-12-2002 |
| | | | HR 960272 A1 | 31-08-1997 |
| | | | HU 9802300 A2 | 28-10-1999 |
| | | | IL 122464 A | 23-05-2002 |
| | | | JP 11509175 T | 17-08-1999 |
| | | | JP 3193058 B2 | 30-07-2001 |
| | | | NO 975700 A | 05-12-1997 |
| | | | NZ 308619 A | 28-01-2000 |
| | | | PL 324660 A1 | 08-06-1998 |
| | | | PT 832082 T | 29-04-2002 |
| | | | SI 832082 T1 | 30-04-2002 |
| | | | SK 168097 A3 | 06-05-1998 |
| | | | TR 9701502 T1 | 21-03-1998 |
| | | | US 6060475 A | 09-05-2000 |
| | | | US 6258817 B1 | 10-07-2001 |
| | | | US 5866568 A | 02-02-1999 |
| | | | ZA 9604615 A | 09-12-1996 |
| WO 0144239 | A | 21-06-2001 | AU 2092601 A | 25-06-2001 |
| | | | CA 2395088 A1 | 21-06-2001 |
| | | | EP 1237888 A2 | 11-09-2002 |
| | | | JP 2003520785 T | 08-07-2003 |
| | | | WO 0144239 A2 | 21-06-2001 |
| | | | US 2002143024 A1 | 03-10-2002 |
| WO 0249630 | A | 27-06-2002 | AU 4173602 A | 01-07-2002 |
| | | | WO 0249630 A2 | 27-06-2002 |
| | | | US 2002082285 A1 | 27-06-2002 |
| WO 0160370 | A | 23-08-2001 | AU 7961400 A | 27-08-2001 |
| | | | BR 0017120 A | 14-01-2003 |
| | | | CA 2395711 A1 | 18-07-2002 |
| | | | CN 1434715 T | 06-08-2003 |
| | | | EP 1256344 A1 | 13-11-2002 |
| | | | HU 0204139 A2 | 28-05-2003 |
| | | | WO 0160370 A1 | 23-08-2001 |
| | | | JP 2001302514 A | 31-10-2001 |